ClinConnect ClinConnect Logo
Search / Trial NCT05530551

Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA

Launched by SOREN OVERGAARD · Sep 3, 2022

Trial Information

Current as of July 08, 2025

Active, not recruiting

Keywords

Antibiotic Prophylaxis Oa Osteoarthritis Osteoarthritis, Hip Total Hip Replacement Total Hip Arthroplasty Prosthetic Joint Infection Pji Cluster Randomized Controlled Trial Randomized Controlled Trial Rct Tha

ClinConnect Summary

This clinical trial is studying the effect of giving either one dose or multiple doses of antibiotics to prevent infections in patients undergoing total hip replacement surgery due to osteoarthritis. The goal is to find out if a single dose of antibiotics given within 24 hours before or after surgery is just as effective as giving several doses. This research involves around 20,000 patients across various hospitals in Denmark.

To participate in this trial, you need to be an adult between the ages of 65 and 74 who is having a total hip replacement surgery for osteoarthritis. However, if your surgery is due to a fracture or a bone tumor, you won't be eligible. If you join the study, you'll be randomly assigned to receive either the single or multiple doses of antibiotics, and researchers will monitor you to see if you develop any infections after your surgery. This trial aims to improve treatment options and ensure the best outcomes for patients undergoing this type of surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. All patients receiving a primary Total Hip Arthroplasty (THA) due to primary and secondary causes of osteoarthritis
  • Exclusion Criteria:
  • 1. Patients receiving a primary THA due to either acute or sequelae of proximal femoral or acetabular fractures
  • 2. Patients receiving a primary THA due to bone tumor or metastasis

About Soren Overgaard

Soren Overgaard is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical development and a focus on innovative therapeutic solutions, Overgaard leads initiatives that prioritize patient safety and regulatory compliance. The organization is renowned for its collaborative approach, working closely with healthcare professionals, regulatory bodies, and research institutions to facilitate the efficient design and execution of clinical studies. Through rigorous methodologies and a commitment to scientific integrity, Soren Overgaard strives to contribute to the future of healthcare by bringing new therapies to market and enhancing the understanding of various medical conditions.

Locations

Aalborg, , Denmark

Aalborg, , Denmark

Aarhus C, , Denmark

Aarhus, , Denmark

Aarhus, , Denmark

Brøndby, , Denmark

Copenhagen Nv, , Denmark

Copenhagen ø, , Denmark

Esbjerg, , Denmark

Farsø, , Denmark

Farum, , Denmark

Frederikshavn, , Denmark

Grindsted, , Denmark

Hellerup, , Denmark

Hellerup, , Denmark

Herlev, , Denmark

Herning, , Denmark

Hillerød, , Denmark

Holbæk, , Denmark

Horsens, , Denmark

Hvidovre, , Denmark

Kongens Lyngby, , Denmark

Kruså, , Denmark

Køge, , Denmark

Næstved, , Denmark

Odense, , Denmark

Randers, , Denmark

Ringsted, , Denmark

Rønne, , Denmark

Silkeborg, , Denmark

Søborg, , Denmark

Vejle, , Denmark

Vejle, , Denmark

Viborg, , Denmark

Aabenraa, , Denmark

Nykøbing Falster, , Denmark

Patients applied

0 patients applied

Trial Officials

Armita A Abedi, MD

Principal Investigator

Copenhagen University Hospital Bispebjerg, Department of Orthopaedic Surgery and Traumatology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials